Stryker (SYK) Stock Forecast & Price Target

Stryker is supported by a market-leading position in orthopedic robotics, leadership in operating room equipment, and a broad portfolio spanning implants, capital equipment, and neurotechnology, which has helped it consistently gain share in attractive medical device categories. Its FY26 organic sales growth guidance of 8.0%-9.5% and adjusted diluted EPS guidance of $14.90-$15.10 underscore resilient demand, while expectations for 30 bps+ operating margin expansion and double-digit EPS growth point to continued operating leverage. The company’s strong capital product backlogs, robust trauma and extremities growth, and roughly one-fourth of revenue from outside the United States also support a durable, diversified growth profile with upside from innovation and international expansion.

Stryker is facing a tougher fundamental setup as seasonal summer softness, a cyberattack-related disruption, and continued peripheral vascular supply constraints pressure near-term procedure volumes and sales. Its Europe-exposed hip franchise is also being hit by government funding trade-offs, hospital strikes, and war-related disruption, while the absence of a commercially available hip impactor leaves it competitively constrained. Although management still expects 2026 organic revenue growth of 8.3% and adjusted EPS of $14.96, those figures sit near the low end of guidance and suggest limited cushion if competition, pricing pressure, or slower product adoption worsens.